VTE-BLEED Score

VTE-BLEED Score

VTE-BLEED is a bleeding risk prediction tool for patients with venous thromboembolism (VTE) who are on stable, long-term anticoagulation — it's specifically designed to inform the decision of whether to extend anticoagulation beyond the initial 3–6 month treatment period, distinguishing it from RIETE (which predicts early bleeding, in the first 90 days).

Development

The score was derived and validated by Klok et al. (European Respiratory Journal, 2016) using a patient-level post hoc analysis of the RE-COVER and RE-COVER II trials, restricted to the dabigatran treatment arms (chosen for dabigatran's early stable anticoagulant effect compared to warfarin). Using logistic regression, six variables emerged as significant predictors of major or clinically relevant non-major bleeding occurring after the first 30 days of anticoagulation. It has since been externally validated in warfarin-treated patients from the same trial program, and in both the edoxaban and warfarin arms of the Hokusai-VTE trial.

The Six Components

Definitions:

1. Cancer diagnosed within 6 months before VTE diagnosis (excluding basal-cell or squamous-cell skin carcinoma), or recently recurrent/progressive cancer, or any cancer requiring anti-cancer treatment within the prior 6 months

2. Systolic blood pressure ≥140 mmHg at baseline, in men only

3. Hemoglobin <13 g/dL in men or <12 g/dL in women

4. Prior major or non-major clinically relevant bleeding event, rectal bleeding, frequent nosebleeds, or hematuria

5. Glomerular filtration rate <60 mL/min

Risk Categories

The 2-point threshold was specifically chosen because it optimally separated low- and high-risk groups in the derivation data. Note that with 1.5-point increments, a patient can land just under the threshold (e.g., 1.5) or just at/over it (2.0) with relatively small differences in risk factor burden — worth keeping in mind when interpreting borderline scores.

Definitions

Major bleeding (from International Society of Thrombosis and Hemostasis):

• Fatal bleeding and/or

• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or

• Bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of two or more units of whole blood or red cells.

Clinically relevant bleeding: rectal bleeding, frequent nose bleeds, or hematuria.

Management Considerations

• Consider closer monitoring and review of anticoagulation intensity and duration, especially during higer-risk periods (e.g., around provedures).

• For high risk, consider adjustments to the anticoagulation approach, such as:

  • Careful medication selection (e.g., DOAC versus VKA).

  • Dose adjustment (e.g., prophylactic versus therapeutic dosing after a designated period).

  • Shorter anticoagulation duration (e.g., 3 months versus 6 months).

• Consider applicable non-anticoagulant strategies.

• Assess for active or recent bleeding before starting or continuing anticoagulation. 

• Consider addressing modifiable risk factors for bleeding.

• Do not use this tool in patients with severe renal impairment (creatinine clearance <30 mL/min).

• Clinical judgement and best practice guidelines (e.g. 2026 AHA Guideline for the Evaluation and Management of Acute PE in Adults) supersedes adjunct standalone decision tools.

• Risk and benefits of anti-coagulation should be considered in patients, to include shared decision-making and informed consent, prior to initiating therapy. 

Clinical Guidelines

• AHA/ACC/ACCP - Evaluation and management of acute PE in adults.

• ESC - Diagnosis and management of acute PE

Performance

The score achieved a c-statistic of 0.72 (95% CI 0.67–0.76) in derivation. Across derivation and validation studies, the odds ratio for major bleeding in the high-risk group (≥2 points) compared to the low-risk group ranged from 3.1 to 6.5 — indicating a substantial risk increase — and this relationship held even when the analysis was restricted to just fatal or intracranial bleeding events. VTE-BLEED is notable for being the only externally validated VTE bleeding score tested across all three major anticoagulant mechanisms: vitamin K antagonists, direct thrombin inhibitors (dabigatran), and direct factor Xa inhibitors (edoxaban, rivaroxaban).

A separate study found that VTE-BLEED performed similarly to the RIETE score by AUC (0.69–0.72 for both), though VTE-BLEED classified a much larger proportion of patients as high-risk (62.3%) compared to RIETE (7.1%) — a substantial practical difference despite similar discrimination, worth considering when choosing between the two.

Practical Use

Per its clinical guidance, a score ≥2 should prompt consideration of closer monitoring (especially around high-risk periods like procedures), careful anticoagulant selection (DOAC vs. vitamin K antagonist), dose adjustment, shorter treatment duration, and management of modifiable risk factors — rather than automatic discontinuation of anticoagulation.

Klok FA, Hösel V, Clemens A, Yollo WD, Tilke C, Schulman S, Lankeit M, Konstantinides SV. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J. 2016 Nov;48(5):1369-1376.